Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... 15, 2014 Investor-Edge has initiated coverage ... ), Eli Lilly and Company (NYSE: LLY ), ... SNY ), and Novartis AG (NYSE: NVS ... at: http://investor-edge.com/register . On Friday, December 12, ... Dow Jones Industrial Average lost 1.79%, to finish the day ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... and development company, is pleased to announce the grant ... States relating to its GPCR-focused drug discovery ... significantly strengthens the global patent estate covering Heptares, technologies ... The suite of patents recently granted by the US ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... 12, 2011 Southern Home Medical Equipment, Inc. ... healthcare professionals and equipment to medical institutions, announced ... operations for fiscal year 2010 have been restated ... Medical Staffing. In a previous announcement ...
... Inc., a privately held medical device company focused on ... announced the initial launch of its Durango™ Stand-Alone ALIF ... was made at the 2011 American Association of Neurological ... The Durango system is intended to treat degenerative disc ...
Cached Medicine Technology:Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2Lanx®, Inc. Launches Durango™ Stand-Alone ALIF System 2
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
(Date:12/17/2014)... Greater participation in music classes may benefit children,s language ... in the nonprofit Harmony Project, which provides music education ... Over two years, children who actively participated in the ... speech and reading, compared to those with lower levels ... in music classes occurred in the same areas of ...
(Date:12/15/2014)... researchers have just published an important new report on ... mesothelioma. Surviving Mesothelioma has just posted an article on ... read it now. , Doctors at Harvard, MIT, ... Langone Medical Center performed complete genetic analyses on 22 ... to pinpoint the genes that are most likely to ...
(Date:12/15/2014)... OutMarket , a provider of marketing ... Cheat Sheets ,” a guide that exposes the insider ... the top ten social media networks. , Social ... engagement, and customer service. It can also increase new ... on new networks and weather constantly changing algorithms, they ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3
... The American Association of Cardiovascular and Pulmonary Rehabilitation ... Los Angeles Biomedical Research Institute (LA BioMed) principal ... annual meeting in Milwaukee. Dr. Casaburi, who ... the Rehabilitative Sciences at LA BioMed and leads ...
... As a patient safety best practice and endorsement of ... Board of Directors approved and released a clinical practice ... procedure called vertebroplasty as a way to treat fractures ... avenue the Academy uses to ensure that patients receive ...
... By Steven Reinberg HealthDay Reporter , ... popular misconception that because sports drinks and other noncarbonated ... healthy, University of Texas researchers report. In a ... students throughout Texas, researchers found that kids who drank ...
... ago, the discovery of microRNAs ― tiny cellular molecules ... of scientific possibilities, including a deeper understanding of human ... gives scientists the ability to discover invaluable information about ... University researchers have developed the cutting-edge technology to better ...
... in daycare puts children with a chronic lung condition ... infections, according to a study from Johns Hopkins Children,s ... . The researchers say their findings should ... of age, for signs of lung disease and to ...
... SEPTEMBER 24, 2010 Lillian Feldshuh, of Scarsdale, NY, ... 2006, received the Courageous Patient Award yesterday at the ... DC. The procedure was a success and Feldshuh, who ... in good health. In 2006, Lillian Feldshuh suffered ...
Cached Medicine News:Health News:LA BioMed researcher to receive prestigious honor 2Health News:New guideline finds no evidence for a popular back procedure 2Health News:New guideline finds no evidence for a popular back procedure 3Health News:Study Finds Teens Think Sports Drinks Are Healthy 2Health News:Study Finds Teens Think Sports Drinks Are Healthy 3Health News:Diving deeper into the gene pool 2Health News:Daycare puts children with lung disease at risk for serious illness 2
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... Tupos LA, the only ICD system in ... the first implant for the treatment of ... a lasting improvement of their hemodynamics and ... LA uses biatrial stimulation to effectively suppress ...
Medicine Products: